
Novartis Financial Results - Q3 2018

Novartis delivered strong growth and innovation during the third quarter



"We progressed our breakthrough medicines pipeline including our leading advanced therapy platforms in cell and gene and continued our strong operational performance."





Advanced Therapy Platforms

AVXS-101 simultaneous global submissions in US, EU and Japan² for SMA Type 1



More than 90% of children diagnosed with SMA Type 1, will die or need permanent ventilation support by the age of 2.⁴

1 Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Interim Financial Report. Unless otherwis noted, all growth rates in this Release refer to same period in prior year. 2 Nitisted submission in mid-September, anticipate completion by year end.

3 Copaxone® is a registered trademark of Teva Pharmaceutical Industries Ltd.

4 Darras B.T., et al. Spinal Muscular Atrophy. Chapter 25 - Natural History of Spinal Muscular Atrophy. October 2016.

\rm 🕑 NOVARTIS